Leila E Mansoor

Dados Biográficos

ID	7727293
NOME	Leila E Mansoor
PRENOMES	Leila E
SOBRENOME	Mansoor
ASSINATURA	MANSOOR L E
AFILIAÇÕES	Centre for the AIDS Programme of Research in South Africa
ORCID	0000-0002-7607-348X
VERIFICADO	Sim
TOTAL DE OBRAS	30
TOTAL DE CITAÇÕES	0
TOTAL COMO AUTOR	30
TOTAL COMO EDITOR	0
PRIMEIRO ANO DE PUBLICAÇÃO	2010
ANO MAIS RECENTE DE PUBLICAÇÃO	2026
ÍNDICE H	0

Evaluating Motivational Interviewing and Peer Adherence Support as Strategies to Improve Oral PrEP Adherence among HIV-Negative Adults in KwaZulu-Natal, South Africa
Open AccessSherishka Dhindayal, Sanele Mbeje et al.ARTICLEAIDS and Behavior2026
Consistent adherence is essential for the effectiveness of daily oral pre-exposure prophylaxis (PrEP) in preventing HIV. Motivational interviewing (MI) and peer adherence support (PAS) are adherence support strategies, providing individualized support and may enhance both adherence to oral PrEP and continued use over time. This study aimed to evaluate the impact of implementation-adapted MI and PAS approaches on oral PrEP adherence and identify p…
Written on the Skin
Open AccessEmma Durden, Eliza Govender et al.ARTICLEAIDS and Behavior2026
To address challenges associated with the uptake of daily oral pre-exposure prophylaxis (PrEP) by young women at high risk of acquiring HIV, a range of novel, long-acting, slow-release products are being developed and clinically evaluated. One such technology is an annual implant of tenofovir alafenamide (TAF). This study explores the perspectives of participants from a first-in-human trial of an annual TAF implant to inform considerations for fu…
“There is nobody who wouldn’t like to”
Open AccessEmma Durden, Eliza Govender et al.ARTICLEAIDS Care2026
A novel long-acting HIV oral pre-exposure prophylaxis (PrEP) implant was first tested in a Phase I clinical trial in South Africa, and this study sought to understand motivations behind trial participants enrolment, highlighting considerations for recruitment in future studies. Qualitative research was conducted using in-depth interviews (IDIs) with 29 study participants, 18 of whom also participated in focus group discussions (FGDs). Participant…
Acceptability of the dapivirine vaginal ring for HIV-1 prevention among women reporting engagement in transactional sex
Erica N Browne, Kristine Torjesen et al.ARTICLEAIDS Care2024
We assessed if acceptability of the dapivirine vaginal ring for HIV prevention differed among the subgroup of women who reported engaging in transactional sex prior to enrollment in MTN-020/ASPIRE (phase III trial in Malawi, South Africa, Uganda, and Zimbabwe, 2012-2015; n = 2629). Transactional sex was defined as receipt of money, goods, gifts, drugs, or shelter in exchange for sex in the past year. Dimensions of acceptability included: ease of …
Women’s motivations for participating in the dapivirine vaginal ring open label extension study
Kalendri Naidoo, Elizabeth Montgomery et al.ARTICLEAIDS Care2024
Open-Label Extension (OLE) studies are important in the drug development process and are used to further support the licensing applications and regulatory approvals of products. We aimed to understand why women chose to join the HOPE OLE study – where women were offered the dapivirine vaginal ring after two pivotal trials were completed – through data collected from individual in-depth interviews. Ten women at each of the six HOPE research sites …
Efficacy of the Dapivirine Vaginal Ring Accounting for Imperfect Adherence
Open AccessMarla Husnik, Renee Heffron et al.ARTICLEAIDS and Behavior2024
Key stakeholders’ perspectives on providing oral pre-exposure prophylaxis as HIV-prevention standard of care in clinical trials in South Africa
Ivana Beesham, Cecilia Milford et al.ARTICLEAfrican Journal of AIDS Research2023
Introduction : HIV-prevention and endpoint-driven clinical trials enrol individuals at substantial risk of HIV. Recently, these trials have provided oral pre-exposure prophylaxis (PrEP) as HIV-prevention standard of care; however, data on PrEP uptake and use during the trial and post-trial access are lacking. Methods : We conducted once-off, telephonic, in-depth interviews from August 2020 to March 2021, with 15 key stakeholders (including site d…
Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa
Open AccessIvana Beesham, Cecilia Milford et al.ARTICLEBMC Public Health2023
We identified several barriers to post-trial PrEP access. Strategies to enhance PrEP access such as a reduction in waiting queues, convenient facility operating hours, and making PrEP more widely available and accessible are needed. It is also worth noting that oral PrEP access has expanded in South Africa from 2018 till now and this could improve access to PrEP for participants exiting trials who desire to continue PrEP
Experience with Contraceptive Dosage Forms and Interest in Novel PrEP Technologies in Women
Open AccessClaudia Juliette Jansen van Vuuren, Lara Lewis et al.ARTICLEAIDS and Behavior2023
New pre-exposure prophylaxis (PrEP) strategies tailored to the needs and expectations of individuals at risk of HIV acquisition are needed. In the CAPRISA 082 prospective cohort study in KwaZulu-Natal, South Africa, sexually active women aged 18 to 30 reported, through interviewer-administered questionnaires, on their prior contraceptive experience and interest in both approved and potential future PrEP dosage forms (oral PrEP, long-acting inject…
Daily Oral Pre-exposure Prophylaxis (PrEP) Continuation Among Women from Durban, South Africa, Who Initiated PrEP as Standard of Care for HIV Prevention in a Clinical Trial
Open AccessIvana Beesham, Dvora Joseph Davey et al.ARTICLEAIDS and Behavior2022
HIV incidence among women in Eastern and Southern Africa remains unacceptably high, highlighting the need for effective HIV prevention options, including pre-exposure prophylaxis (PrEP). The Evidence for Contraceptive Options and HIV Outcomes trial offered daily oral PrEP to participants during the latter part of the clinical trial as an additional HIV prevention choice. We explored daily oral PrEP continuation at trial exit among women enrolled …
Correlates of Dapivirine Vaginal Ring Acceptance among Women Participating in an Open Label Extension Trial
Open AccessBrenda Gati Mirembe, Maria Valdez Cabrera et al.ARTICLEAIDS and Behavior2022
Ring-ing in the Future
Open AccessKrishnaveni Reddy, Florence Mathebula et al.ARTICLEAIDS and Behavior2022
Integrating Gender-Based Violence Screening and Support into the Research Clinic Setting
Open AccessMorgan Garcia, Sarah T Roberts et al.ARTICLEAIDS and Behavior2022
HIV and gender-based violence (GBV) are syndemic in sub-Saharan Africa and provision of support for participants who disclose GBV constitutes part of comprehensive care. Consequently, a process was undertaken to develop, implement, and evaluate standard operating procedures (SOPs) in MTN-025/HOPE, a study of the dapivirine vaginal ring for HIV prevention. The SOP was developed using needs assessment surveys in addition to World Health Organizatio…
Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/Aspire study
Open AccessMorgan Garcia, Ellen Luecke et al.ARTICLEBMC Public Health2021
Our analysis supports the growing body of work illustrating the importance of meaningfully engaging research participants to achieve study success and aligns with other analyses of adherence support efforts during ASPIRE. While causation between PEA attendance and product use cannot be established, residual drug levels in returned rings strongly correlated with participant attendance at PEAs, and the benefits of incorporating PEAs should be consi…
Using Emoji Stickers to Understand End-User Opinions of the Dapivirine Vaginal Ring for HIV Prevention
Open AccessAriana Katz, Leila E Mansoor et al.ARTICLEAIDS and Behavior2021
Does the Ring Work? Perceptions and Understanding of the Efficacy of a Dapivirine Vaginal Ring for HIV Prevention Amongst Women in a Placebo-Controlled Trial
Open AccessJuliane Etima, Ariana Katz et al.ARTICLEAIDS and Behavior2021
Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention
Open AccessMarla Husnik, Elizabeth R Brown et al.ARTICLEAIDS and Behavior2021
Men’s Sexual Experiences with the Dapivirine Vaginal Ring in Malawi, South Africa, Uganda and Zimbabwe
Open AccessElizabeth Montgomery, Ariana Katz et al.ARTICLEAIDS and Behavior2021
The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence
Open AccessMarie C D Stoner, Elizabeth R Brown et al.ARTICLEAIDS and Behavior2021
Exploring the Use of Oral Pre-exposure Prophylaxis (PrEP) Among Women from Durban, South Africa as Part of the HIV Prevention Package in a Clinical Trial
Open AccessIvana Beesham, Renee Heffron et al.ARTICLEAIDS and Behavior2020
HIV endpoint-driven clinical trials in Africa enroll women who are at heightened risk of acquiring HIV. In 2017, the South African Medical Research Council recommended the provision of oral pre-exposure prophylaxis (PrEP) in HIV prevention trials, at which time the Evidence for Contraceptive Options and HIV Outcomes trial was ongoing and began to provide PrEP on-site at some trial sites. We interviewed 132 women who initiated PrEP on-site at the …
Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa
Eliza Govender, Eliza M Govender et al.ARTICLEAIDS Care2017
Young women bear a disproportionately high burden of HIV infection in sub-Saharan Africa, prioritising pre-exposure prophylaxis (PrEP) can be an integral part of HIV prevention combination strategies. Women initiated HIV prevention technology options will require consistent adherence, an imperative for product effectiveness. With several PrEP clinical trials underway; exploring women's acceptability to advances in HIV prevention technologies can …
Secrecy, empowerment and protection
Eliza Govender, Leila Mansoor et al.ARTICLECulture Health & Sexuality2017
for all populations at high risk of acquiring HIV opens the way for implementation of oral pre-exposure prophylaxis (PrEP). The impact of new prevention technologies is, however, dependent on demand creation strategies such as user awareness, acceptability and access, which in turn are influenced by sociocultural and gender norms. This study was conducted in three locations in KwaZulu-Natal, urban, rural and peri-urban, with six participatory wor…
Social Context of Adherence in an Open-Label 1 % Tenofovir Gel Trial
Open AccessKathleen M Macqueen, Sarah Dlamini et al.ARTICLEAIDS and Behavior2016
CAPRISA 008, an open-label extension study of tenofovir gel with coitally-related dosing, provided an opportunity to explore the relationship between product adherence and gender dynamics in a context where women knew they were receiving an active product with evidence of HIV prevention effectiveness. Interviews with 63 CAPRISA 008 participants and 13 male partners in KwaZulu-Natal, South Africa, highlighted that the process of negotiating gel us…
Measurement of Vaginal Microbicide Adherence Using Visual Inspection as Compared to Ultra Violet Light Assessment of Returned Empty Gel Applicators
Open AccessMichele Upfold, Anneke Grobler et al.ARTICLEAIDS and Behavior2016
Disclosure of Microbicide Gel Use to Sexual Partners
Open AccessKathryn Mngadi, Kathryn Therese Mngadi et al.ARTICLEAIDS and Behavior2014